¹ú¼ÊÃ×À¼¶ÔÕó¿ÆĪ

The incidence of heart attacks and strokes was lower after COVID-19 vaccination than before or without vaccination, according to a new study involving nearly the whole adult population of England.

Researchers have developed a new vaccine technology that has been shown in mice to provide protection against a broad range of coronaviruses with potential for future disease outbreaks - including ones we don’t even know about

Researchers have discovered that misreading of therapeutic mRNAs by the cell’s decoding machinery can cause an unintended immune response in the body. They have identified the sequence within the mRNA that causes this to occur and found a way to prevent ‘off-target’ immune responses to enable the safer design of future mRNA therapeutics.

Studies of a ‘future-proof’ vaccine candidate have shown that just one antigen can be modified to provide a broadly protective immune response in animals. The studies suggest that a single vaccine with combinations of these antigens – a substance that causes the immune system to produce antibodies against it – could protect against an even greater range of current and future coronaviruses.

Recruitment is underway in ¹ú¼ÊÃ×À¼¶ÔÕó¿ÆĪ for volunteers to take part in clinical trials of a revolutionary new needle-free vaccine to protect against SARS-CoV-2 – the virus that causes COVID-19 – and related coronaviruses.

Referrals to ¹ú¼ÊÃ×À¼¶ÔÕó¿ÆĪ’s long COVID clinic fell dramatically in the period August 2021 to June 2022, which researchers say is likely due to the successful rollout of the vaccine.

Prime Minister Boris Johnson announced that DIOSynVax, a biotech spinout of the ¹ú¼ÊÃ×À¼¶ÔÕó¿ÆĪ, will receive $42 million (about £32 million) to develop a vaccine candidate that could provide protection against both existing and future variants of SARS-CoV-2 – the virus that causes COVID-19 – as well as other major coronaviruses, including those that cause SARS and MERS.

The Omicron variant of SARS-CoV-2 may be significantly better than previous variants at evading vaccine-induced antibodies, according to new research from ¹ú¼ÊÃ×À¼¶ÔÕó¿ÆĪ – but preliminary evidence suggests it is less likely to cause severe COVID-19 illness in the lungs.

Safety trials are underway for a vaccine developed by ¹ú¼ÊÃ×À¼¶ÔÕó¿ÆĪ researchers that could be used as a booster targeting COVID-19 virus variants and relatives that threaten future coronavirus pandemics.

Diphtheria – a relatively easily-preventable infection – is evolving to become resistant to a number of classes of antibiotics and in future could lead to vaccine escape, warn researchers from the UK and India.